[{"orgOrder":0,"company":"Zentiva","sponsor":"Mabxience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Bevacizumab","moa":"||Vascular endothelial growth factor A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zentiva","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zentiva \/ Zentiva","highestDevelopmentStatusID":"15","companyTruncated":"Zentiva \/ Zentiva"},{"orgOrder":0,"company":"Zentiva","sponsor":"Lupin Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Raltegravir Potassium","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Zentiva","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Zentiva \/ Zentiva","highestDevelopmentStatusID":"15","companyTruncated":"Zentiva \/ Zentiva"},{"orgOrder":0,"company":"Zentiva","sponsor":"Cinclus Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Linaprazan Glurate","moa":"P-CAB","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Zentiva","amount2":0.25,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.25,"dosageForm":"Oral Tablet","sponsorNew":"Zentiva \/ Zentiva","highestDevelopmentStatusID":"8","companyTruncated":"Zentiva \/ Zentiva"},{"orgOrder":0,"company":"Zentiva","sponsor":"Tillomed Laboratories Ltd","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Zentiva","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zentiva \/ Zentiva","highestDevelopmentStatusID":"1","companyTruncated":"Zentiva \/ Zentiva"},{"orgOrder":0,"company":"Zentiva","sponsor":"Mithra Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"BELGIUM","productType":"Hormone","year":"2020","type":"Agreement","leadProduct":"Etonogestrel","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Zentiva","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal","sponsorNew":"Zentiva \/ Zentiva","highestDevelopmentStatusID":"15","companyTruncated":"Zentiva \/ Zentiva"},{"orgOrder":0,"company":"Zentiva","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Zentiva","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Zentiva \/ Zentiva","highestDevelopmentStatusID":"15","companyTruncated":"Zentiva \/ Zentiva"},{"orgOrder":0,"company":"Zentiva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CZECH REPUBLIC","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Abiraterone Acetate","moa":"Cytochrome P450 17A1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Zentiva","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zentiva \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zentiva \/ Inapplicable"},{"orgOrder":0,"company":"Zentiva","sponsor":"Biocon","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Peptide","year":"2022","type":"Agreement","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Zentiva","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Zentiva \/ Zentiva","highestDevelopmentStatusID":"15","companyTruncated":"Zentiva \/ Zentiva"},{"orgOrder":0,"company":"Zentiva","sponsor":"Adalvo","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"MALTA","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Zentiva","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zentiva \/ Zentiva","highestDevelopmentStatusID":"1","companyTruncated":"Zentiva \/ Zentiva"}]

Find Clinical Drug Pipeline Developments & Deals by Zentiva

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Under the licensing agreement, Zentiva will hold the rights for the commercialization and manufacturing of linaprazan glurate, in Europe.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : $14.7 million

                          May 22, 2025

                          Lead Product(s) : Linaprazan Glurate

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase II

                          Recipient : Cinclus Pharma

                          Deal Size : $249.2 million

                          Deal Type : Licensing Agreement

                          blank

                          02

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Raltegravir is an approved, small molecule, HIV-1 integrase inhibitor, available as a film coated tablet for the treatment of HIV in adult and paediatric patients weighing at least 40kg.

                          Product Name : Raltegravir-Generic

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 22, 2024

                          Lead Product(s) : Raltegravir Potassium

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Recipient : Lupin Ltd

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Liraglutide-Generic is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is indicated for the treatment of patients with type 2 diabetes mellitus.

                          Product Name : Liraglutide-Generic

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          March 28, 2024

                          Lead Product(s) : Liraglutide

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved FDF

                          Recipient : Biocon

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Under the terms of collaboration, Zentiva will complement their product offering with the support of longstanding partners Adalvo with new molecules in a variety of therapeutical areas like Respiratory, CNS and Dermatology.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          September 01, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Undisclosed

                          Recipient : Adalvo

                          Deal Size : Undisclosed

                          Deal Type : Expanded Collaboration

                          blank

                          05

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Through this acquisition, Zentiva will significantly increase its position in the Hospital sector and more specifically in the Oncology area with some value-added 16 products complementing the products recently launched.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          December 16, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Recipient : Tillomed Laboratories Ltd

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          06

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Under the terms of this agreement Biocon will be responsible for the manufacturing and supply of Liraglutide to Zentiva, for its commercialization across 30 countries in Europe.

                          Product Name : Liraglutide-Generic

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          November 23, 2022

                          Lead Product(s) : Liraglutide

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Undisclosed

                          Recipient : Biocon

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          07

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Alymsys (bevacizumab-maly) is a vascular endothelial growth factor inhibitor for the treatment of metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first or second-line treatment.

                          Product Name : Alymsys

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          September 04, 2021

                          Lead Product(s) : Bevacizumab,Fluorouracil,Calcium Folinate

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Recipient : Mabxience

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          08

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Mithra grants license to Zentiva for commercialization of its vaginal contraceptive ring in three key European markets.

                          Product Name : Myring

                          Product Type : Hormone

                          Upfront Cash : Undisclosed

                          June 07, 2020

                          Lead Product(s) : Etonogestrel,Ethinyl Estradiol

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Approved FDF

                          Recipient : Mithra Pharmaceuticals

                          Deal Size : $2.2 million

                          Deal Type : Agreement

                          blank

                          09

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 04, 2020

                          Lead Product(s) : Abiraterone Acetate

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank